Nemaura Medical Inc (NASDAQ:NMRD) has launched shipments of its SugarBEAT continuous glucose monitors to patients in the United Kingdom, the company announced Wednesday.
The wave of shipments is the company’s first foray into the European market after receiving its CE mark, an EU seal of approval, in May.
The SugarBEAT monitor works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle to puncture the skin and draw a blood sample.
“We are very pleased to have commenced the first phase of our commercial launch,” CEO Faz Chowdhury said in a statement. “This represents a major achievement for the company as we transition from product development to a full-fledged commercial organization.”
The company already has an eager British clientele. Nemaura reported that its UK licensee has registered more than 17,000 expressions of interest from potential users on its website.
The Loughborough, England-based company plans to present data from its first European users at the European Association for the Study of Diabetes conference in Barcelona on September 19.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel